Since it began, the COVID-19 pandemic has been a highly dynamic situation. New developments in the pandemic have led to new evidence, which, in turn, have informed new or refined public health guidance.
As you may know, Canadian public health guidance around the AstraZeneca COVID-19 vaccine has evolved in recent weeks, in part due to concerns around vaccine-induced immune thrombotic thrombocytopenia (VITT, also known as vaccine-induced prothrombotic immune thrombocytopenia/VIPIT), which has been reported following post-licensure use of the vaccine in several countries.
The Public Health Agency of Canada is committed to addressing the evolving COVID-19 vaccine-related knowledge and training needs of health care providers. We will continue to offer webinars, and other training opportunities, to health care providers, to share the latest evidence and guidance with you on authorized COVID-19 vaccines, vaccine safety and related topics.
In the meantime, The Public Health Agency of Canada has prepared a short information bulletin on AstraZeneca and VITT .
The bulletin compiles statements and guidance documents on these topics from a number of federal and provincial sources.
If you have any questions or comments, please share them through email at [email protected].